Prenatal stress as possible aetiogenetic factor of homosexuality in human males.
PubMedPublished 1 June 1980
G Dörner, Timothy J. Geier, L.H. Ahrens, L Krell, G Münx, H Sieler
Citations85
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Out of 865 homosexual males who were registered by venerologists in 6 districts of the GDR highly significantly more homosexuals were born during the stressful war and early postwar period of the Second World War than in the years before or after this critical period, suggesting that stressful prenatal (or perinatal) events may represent an aetiogenetic factor for homosexuality in human males.
Abstract
Out of 865 homosexual males who were registered by venerologists in 6 districts of the GDR highly significantly more homosexuals were born during the stressful war and early postwar period of the Second World War, i.e. between 1941 and 1947 (with a maximum of relative frequency in 1944-1945), than in the years before or after this critical period. This finding suggests that stressful prenatal (or perinatal) events may represent an aetiogenetic factor for homosexuality in human males.
Keywords
Medicine
CA A Cancer Journal for CliniciansCancer statistics, 2013
11,899 Citations2013Rebecca L. Siegel, Deepa Naishadham +1 more
Overall cancer death rates have declined 20% from their peak in 1991 to 2009 and can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.
New England Journal of MedicineReduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
10,986 Citations2011Denise R Aberle, Amanda M Adams +8 more
Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.
Journal of Health EconomicsThe price of innovation: new estimates of drug development costs
4,271 Citations2003Joseph A. DiMasi, Ronald W. Hansen +1 more
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms and used to estimate the average pre-tax cost of new drug development.
Nature Reviews Drug DiscoveryCan the pharmaceutical industry reduce attrition rates?
4,111 Citations2004Ismail Kola, J. Richard Landis
The pharmaceutical industry faces considerable challenges, both politically and fiscally, and the fiscal pressures that face the industry from the perspective of R&D are dealt with.
Controlled Clinical TrialsOptimal two-stage designs for phase II clinical trials
3,593 Citations1989Richard Simon
Two-stage designs that are optimal in the sense that the expected sample size is minimized if the regimen has low activity subject to constraints upon the size of the type 1 and type 2 errors are presented.
JAMABenefits and Harms of CT Screening for Lung Cancer
1,230 Citations2012Peter B. Bach, Joshua N. Mirkin +13 more
Low-dose computed tomography screening may benefit individuals at an increased risk for lung cancer, but uncertainty exists about the potential harms of screening and the generalizability of results.
New England Journal of MedicineResults of Initial Low-Dose Computed Tomographic Screening for Lung Cancer
1,090 Citations2013The National Lung Screening Trial Research Team
The NLST initial screening results are consistent with the existing literature on screening by means of low-dose CT and chest radiography, suggesting that a reduction in mortality from lung cancer is achievable at U.S. screening centers that have staff experienced in chest CT.
New England Journal of MedicineSelection Criteria for Lung-Cancer Screening
1,011 Citations2013Martin C. Tammemägi, Hormuzd A. Katki +9 more
The use of the PLCO(M2012) model was more sensitive than the NLST criteria for lung-cancer detection and compared the accuracy of PLCo(M 2012) criteria withNLST criteria to detect lung cancer.
Journal of Clinical OncologyEconomics of New Oncology Drug Development
349 Citations2007Joseph A. DiMasi, Henry G. Grabowski
It was found that approved new oncology drugs to have a disproportionately high share of FDA priority review ratings, of orphan drug designations at approval, and of drugs that were granted inclusion in at least one of the FDA's expedited access programs.
JNCI Journal of the National Cancer InstituteA National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program
323 Citations2010John F. Scoggins, Scott D. Ramsey
Policy makers will need to consider methods to increase patient participation in cancer clinical trials or, alternatively, ways to allocate enrollment between publicly and privately funded clinical trials with a goal of improving clinical trial completion rates.
PharmacoEconomicsThe Value of Improving the Productivity of the Drug Development Process
231 Citations2002Joseph A. DiMasi
Whether faster development times, quicker termination decisions or higher success rates derive from public policy initiatives, better management, or new technologies, the impact on R&D costs can be substantial and result in more innovation and new therapies reaching patients sooner.
Clinical TrialsA predictive probability design for phase II cancer clinical trials
182 Citations2008J Jack Lee, Diane D. Liu
The predictive probability design is efficient and remains robust in controlling type I and type II error rates when the trial conduct deviates from the original design.
JAMAComputed Tomography Screening for Lung Cancer
82 Citations2013Phillip M. Boiselle
Individuals at high risk of lung cancer who meet the criteria for CT screening in published guidelines should participate in an informed and shared decision-making process by discussing the potential benefits, harms, and uncertainties of screening with their physicians.
Health AffairsAre Development Times For Pharmaceuticals Increasing Or Decreasing?
55 Citations2006Salomeh Keyhani, Marie Diener‐West +1 more
Trends in drug development times for 168 drugs with data collected from publicly available sources show clinical trial periods have not increased during this time frame, and regulatory review periods have decreased, suggesting it is unlikely that longer clinical trial times are contributing to rising prescription drug prices.
Clinical Cancer ResearchPhase II Oncology Trials: Let's Be Positive
50 Citations2005Mark J. Ratain
The critical decision in drug development is often at the end of phase II, as phase III trials are an expensive undertaking, with the potential for significant corporate and public consequences in the event of a negative phase III trial.
Clinical Cancer ResearchResampling Phase III Data to Assess Phase II Trial Designs and Endpoints
29 Citations2012Manish Sharma, Theodore Karrison +5 more
Compared with the single-arm design and the randomized design comparing PFS, the randomized phase II design with the log ratio endpoint has greater power to predict the positive phase III result of sorafenib in renal cancer, but a higher false positive rate for the negative phase III Results.
Clinical Cancer ResearchAccelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?
11 Citations2013James C. Yao, Funda Meric‐Bernstam +2 more
Here, the inherent limitations of smaller studies are considered and the strategies for hastening oncology drug development while maintaining high-efficacy standards are discussed.